Fig. 1: Distribution of HRD score and S3 levels according to BRCA 1/2 mutational status and breast cancermolecular subtypes. | npj Breast Cancer

Fig. 1: Distribution of HRD score and S3 levels according to BRCA 1/2 mutational status and breast cancermolecular subtypes.

From: Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

Fig. 1: Distribution of HRD score and S3 levels according to BRCA 1/2 mutational status and breast cancermolecular subtypes.The alternative text for this image may have been generated using AI.

a, b Violin plots representing the distribution of HRD score (a) and signature 3 (b) according to molecular subtype and BRCA 1/2 mutational status. *: significant Wilcoxon test p-value. c, d Violin plots representing the distribution of HRD score (c) and signature 3 (d) according to molecular subtype and BRCA 1/2 mutational status combined with HRD status. Patients were stratified into three groups for each molecular subtype: BRCA 1/2 mutated tumors (red), BRCA1/2 wild type with high-HRD score (or high-S3 level) tumors (green), and BRCA 1/2 wild- type with low-HRD score (or low-S3 level) tumors (blue). *: significant Wilcoxon test p-value.

Back to article page